CYP450 2D6 and 2C19 genotypes in ADHD: not related with treatment resistance but with over-representation of 2C19 ultra-metabolizers

Abstract Objectives Cytochrome P450 (CYP450) is a major enzyme system involved in drug metabolism as well as regulation of brain function. Although individual variability in CYP enzymes have been studied in terms of personality traits and treatment effects, no study up to now evaluated CYP polymorphisms in children with attention deficit/hyperactivity disorder (ADHD). We aimed to define the genetic profiles of CYP2D6 and CYP2C19 relevant alleles in children with ADHD according to treatment status and compare the frequencies according to past results. Methods Three hundred and seventeen patients with ADHD-Combined Presentation were enrolled; symptom severity was evaluated by parents and clinicians while adverse effects of previous treatments were evaluated with parent and child reports. Reverse blotting on strip assays was used for genotyping and descriptive and bivariate analyses were conducted. A p-value was set at 0.05 (two-tailed). Results Children were divided into treatment-naïve (n=194, 61.2%) and treatment-resistant (n=123, 38.8%) groups. Within the whole sample PM, EM and UM status according to 2D6 were 3.8% (n=12), 94.3% (n=299) and 21.9% (n=6); respectively. PM, IM, EM and UM status according to 2C19 were 2.5% (n=8), 19.8% (n=63), 48.6% (n=154) and 29.0% (n=92), respectively. No relationship with treatment resistance, comorbidity or gender could be found. Importantly, CYP2C19 UMs were significantly more frequent in ADHD patients compared to previous studies in the general population. Conclusions CYPs may be a rewarding avenue of research to elucidate the etiology and treatment of patients with ADHD.

[1]  J. Stingl,et al.  CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study , 2021, Frontiers in Pharmacology.

[2]  Xiao-dong Liu,et al.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances , 2021, Frontiers in Pharmacology.

[3]  W. Daniel,et al.  Cytochrome P450 expression and regulation in the brain , 2020, Drug metabolism reviews.

[4]  J. Stingl,et al.  Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain , 2020, bioRxiv.

[5]  J. Stingl,et al.  Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity , 2019, bioRxiv.

[6]  C. Bousman,et al.  Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines? , 2019, Pharmacopsychiatry.

[7]  Lisa J. Martin,et al.  Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders , 2019, Front. Pharmacol..

[8]  S. Faraone,et al.  Genetics of attention deficit hyperactivity disorder , 2018, Molecular Psychiatry.

[9]  G. Özhan,et al.  CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population , 2016, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[10]  Ian R. McGrane,et al.  Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital. , 2016, Journal of child and adolescent psychopharmacology.

[11]  E. Gillam,et al.  Differential Expression of Cytochrome P450 Enzymes from the CYP2C Subfamily in the Human Brain , 2015, Drug Metabolism and Disposition.

[12]  M. Ingelman-Sundberg,et al.  Pharmacogenomics of Cytochrome P450 Dependent Metabolism of Endogenous Compounds: Implications for Behavior, Psychopathology and Treatment , 2014 .

[13]  A. Llerena,et al.  CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials. , 2014, British journal of clinical pharmacology.

[14]  G. Schulte,et al.  Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene , 2013, Molecular Psychiatry.

[15]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[16]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.

[17]  U. Yasar,et al.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood , 2012, European Journal of Clinical Pharmacology.

[18]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[19]  E. Bromek,et al.  Cytochrome P450 mediates dopamine formation in the brain in vivo , 2011, Journal of neurochemistry.

[20]  J Kirchheiner,et al.  CYP2D6 in the brain: genotype effects on resting brain perfusion , 2011, Molecular Psychiatry.

[21]  D. Nelson.  The Cytochrome P450 Homepage , 2009, Human Genomics.

[22]  M. Loriot,et al.  Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function , 2009, Drug Metabolism and Disposition.

[23]  Deborah C. Mash,et al.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment , 2008, Neuropharmacology.

[24]  M. Sikora,et al.  The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[25]  Wei Duan,et al.  Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.

[26]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[27]  A. Seeringer,et al.  Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. , 2007, Biochimica et biophysica acta.

[28]  D. Patel,et al.  Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. , 2007, Disease-a-month : DM.

[29]  J. McCracken,et al.  CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  K. Otani,et al.  CYP2C19 polymorphism affects personality traits of Japanese females , 2007, Neuroscience Letters.

[31]  E. Begg,et al.  Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice , 2006, Pharmacological Reviews.

[32]  U. Ozbek,et al.  CYP2D6 and CYP1A1 mutations in the Turkish population , 2005, Cell biochemistry and function.

[33]  D. Murry,et al.  Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[34]  P. Joyce,et al.  Association between cytochrome P450 2D6 genotype and harm avoidance , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[35]  N. Thuerauf,et al.  CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study , 2004, Clinical pharmacology and therapeutics.

[36]  P. du Souich,et al.  5‐Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide , 2004, British journal of pharmacology.

[37]  K. Miczek,et al.  Neurosteroids, GABAA receptors, and escalated aggressive behavior , 2003, Hormones and Behavior.

[38]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[39]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[40]  M. Eichelbaum,et al.  Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.

[41]  M. Schwartz,et al.  Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia) , 2000, European Journal of Human Genetics.

[42]  G. Murray,et al.  Cytochrome P450 in normal human brain and brain tumours. , 1997, Biochemical Society transactions.

[43]  N. Ryan,et al.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[44]  E. Spina,et al.  Clinical applications of CYP genotyping in psychiatry , 2014, Journal of Neural Transmission.

[45]  Scott C Armstrong,et al.  Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. , 2006, Psychosomatics.

[46]  J. Prince.  Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. , 2006, Child and adolescent psychiatric clinics of North America.

[47]  M Ingelman-Sundberg,et al.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.

[48]  A. Daly.  Development of analytical technology in pharmacogenetic research , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[49]  L. Bertilsson,et al.  Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study , 2003, European Journal of Clinical Pharmacology.